Search
On this page:
Supporting cell culture media manufacturing at scale
Sourcing reliable, high-volume cell culture media for vaccine and biologics manufacturing demands supply continuity, consistent product quality, and a manufacturing infrastructure capable of scaling alongside program requirements. For bioprocess engineers and supply chain leads, a gap at these points could have effects across development and commercial production.
The bioprocessing Paisley, Scotland facility is a large-scale, manufacturing-focused site designed to support both powder and liquid cell culture media production, including sera, with the process controls and harmonized manufacturing processes that commercial programs depend on.
Facility highlights
The location represents a manufacturing-ready environment aligned with relevant regulations, within Thermo Fisher Scientific's global bioprocessing network.
| Highlight | Detail |
| Products | Media, reagents, sera |
| Regulatory status | FDA registered |
| Certifications | ISO 13485, 21 CFR 820 |
| Key manufacturing capabilities |
|
Capabilities that support media production
The facility's powder and liquid manufacturing suites are used to produce cell culture media at scale, support format flexibility across dry powder and liquid formats, and help reduce supply risk for customers.
Powder manufacturing
The Paisley location supports production of dry powder media (DPM) and Gibco Advanced Granulation Technology (AGT) media.
Dry powder media
The AOF dry powder manufacturing infrastructure, including the core dry powder media milling and blending suite and the ribbon blender suite, supports high-volume DPM production with process controls designed to maintain consistent media quality.
Advanced Granulation Technology media
Gibco AGT media is a proprietary granulated dry powder format designed to improve dispersion and reduce dust generation during reconstitution. The dry powder and media manufacturing area supports production of this format, drawing on core resources, including the core DPM milling and blending suite, the core DPM ribbon blender suite, and the AOF 75 ft³ blending suite.
Liquid manufacturing
Liquid manufacturing at the Paisley facility supports cell culture media, sera, and supplements.
Cell culture media
Liquid cell culture media are produced and finished at Paisley using the site's blending and liquid media filling suite infrastructure. These operations reflect harmonized global manufacturing processes applied across the manufacturing network.
Sera
Sera manufacturing at this location is a distinct offering within the site's liquid portfolio. Sera production follows the same quality and process controls applied to liquid cell culture media.
Supplements
Supplemental liquid products enhance cell culture workflows by supplying characterized additives produced under the same quality and process controls used in liquid media manufacturing.
Additional bioprocessing resources
Bioprocessing resources
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.